Protecting Innovation at the Intersection of Software and Life Sciences (Live MBHB Webinar)

Tues., Oct. 16, 2018 | 10:00-11:15 a.m. CT | Live MBHB Webinar via WebEx 

The importance of software in the health care and pharmaceutical industries is undeniable. And the future will see software-based innovation become an even more essential part of diagnosis and treatment modalities, including new applications for artificial intelligence (AI) and other nascent technologies. However, seemingly few pharmaceutical and medical device companies have adapted to this new reality by developing in-house capabilities to evaluate how to protect these technologies. This webinar will examine issues that in-house counsel need to consider, including:

  • IP protection of AI in drug development, personalized medicine, and medical devices.
  • Section 101 problems unique to software applications in the Life Sciences area, including the impact of Vanda and Berkheimer.
  • Non-patent alternatives to protecting Life Sciences Intellectual Property, including trade secret protection.
  • Licensing issues for software in the Life Sciences.  


Presenter(s): MBHB attorneys Grantland Drutchas and Aaron Gin, Ph.D.

McDonnell Boehnen Hulbert & Berghoff LLP is committed to educating clients and friends of the firm with respect to significant developments and trends in the areas of intellectual property law.

NOTE: MCLE credit is not available for this archived recording. 

Access an archived audio version of this webinar here